MAP4K3 and breast cancer: Selective knockdown of MAP4K3 by siRNA leads to a significant reduction in cell viability in five paediatric glioma cell lines as assayed by CellTiter Glo, an effect not seen in 18/20 breast cancer cells (p = 0.0017, pHGG vs breast cancer, t-test) (Additional file 6: Figure S6).